Industry News
ChemGenex receives two ARC linkage grants
Melbourne and California-based ChemGenex Pharmaceuticals (ASX:CXS) has been awarded two linkage project grants worth AUD$525,000 in cash from the Australian Research Council (ARC) over the next three years. [ + ]
EQiTX increases equity in ZingoTX
Melbourne-based biotech managed investment group EQiTX (ASX:EQX) has increased its ownership in pain management company ZingoTX to 54 per cent with an equity instalment of AUD$300,000, bringing its total investment in ZingoTX to $1.9 million. [ + ]
EvoGenix raises $9 million in oversubscribed IPO
Antibody therapeutic developer EvoGenix closed its initial public offer (IPO) today oversubscribed, raising AUD$9 million through the issue of 36 million shares at $0.25. [ + ]
Iatia achieves positive quarter
Microscopy company Iatia (ASX:IAT) will achieve its first positive operating cash flow quarter for the period ended June 30. [ + ]
New Chemeq CEO promises 'fresh eyes'
David Williams, the CEO designate of Perth-based antimicrobial specialist Chemeq (ASX:CMQ), begins his new role on August 1 and is excited about running the company. [ + ]
CSL deal boosts GroPep profits
Adelaide-based GroPep's (ASX:GRO) net profit after tax for the 2004-2005 financial year has been boosted by a one-off tax benefit of AUD$3.4 million, and is now expected to be approximately $6.4 million compared with a previous estimate of $3 million. [ + ]
Biota files claim of up to $430m against GSK
Melbourne-based biopharma Biota Holdings (ASX:BTA) today took the next step in its lawsuit against GlaxoSmithKline (GSK), filing particulars of loss and damage with the Victorian Supreme Court estimated to be in the range of AUD$308 million to $430 million. [ + ]
Life Therapeutics to move more operations to US
Life Therapeutics (ASX:LFE) will relocate two of its three business divisions from Sydney to Atlanta, Georgia in the USA by March 31, 2006. [ + ]
Amrad lands US asthma patent
The US Patent Office has granted Melbourne biopharma Amrad (ASX:AML) a patent on therapeutic antibodies that recognise for a sub-unit of the interleukin-13 (IL-13) receptor implicated in asthma. [ + ]
UQ spin-off secures $3.25m for pain therapy
Spinifex Pharmaceuticals, a drug development company spun out of the University of Queensland, has received a AUD$3.25 million investment commitment to develop therapeutics for the treatment of neuropathic pain. [ + ]
In brief: Psivida, Eqitx, Ellex, BRC, AFT
Following its recent Nasdaq listing, Psivida (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) has appointed the president and CEO of New Jersey-based Chugai Pharma USA, David J Mazzo, as a non-executive director. [ + ]
Chemeq names new CEO
Antimicrobial specialist Chemeq (ASX:CMQ) has named David Williams its new CEO and director, commencing August 1. Williams was formerly CEO of Epic Energy, a gas transmission company. [ + ]
First C3 CellSpray XP patient treated
The first patient has been treated with Clinical Cell Culture's (C3, ASX:CCE) CellSpray XP at Dortmund Hospital in Germany. [ + ]
Consolidation and review for Avastra
With the suspension of its Australian BioWeld Tube clinical trial and the postponement of European clinical trails, the June quarter was one of consolidation and review for Sydney biomaterials company Avastra (ASX:AVS). [ + ]
Expert forum maps impediments to GM crops
Over 100 representatives from industry, researchers, farmers' organisations and government took part in the 'Meeting of the Minds' agbiotech forum in Canberra last week to accurately map out differences in positions relating to the introduction of new genetically modified (GM) crops. [ + ]
